Date: 2011-06-13
Type of information: Fundraising
Company: BliNK Therapeutics (UK)
Investors: Cancer Research Technology (UK) - Kurma Life Sciences Partners (France)
Amount: up to £1.1m as seed financing, the investment to start-up the company, and up to £6.6m in further financing
Funding type: seed financing
Planned used: The funding will be used to launch this spin-out company. Formed jointly with Kurma Life Sciences Partners, BliNK will develop the novel platform to generate therapeutic and diagnostic monoclonal antibodies towards clinically relevant targets. The technology is based on research carried out by the founding scientists Dr Facundo Batista, at Cancer Research UK’s London Research Institute in collaboration with Professor Vincenzo Cerundolo at the University of Oxford. The platform technology provides a new way of activating the immune system’s B cells to produce antibodies in response to a specific antigen.
Others:
Therapeutic area:
